These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from March 13 through March 19, 2025. Source: VerityData

Activist Filings

Algonquin Power $(AQN)$ Starboard Value raised its stake in the utility company to 66,433,000 shares. Starboard Value did so through the purchase of 417,000 Algonquin Power shares from Jan. 13 through Feb. 3, 2025, at per share prices ranging from $4.20 to $4.33, but offset those purchases through the sale of 300,000 Algonquin shares on Feb. 19 at an average price of $4.96. On March 13, Starboard entered into an agreement with Algonquin to appoint Gavin Molinelli to the board immediately following approval by the Federal Energy Regulatory Commission.

Following the latest activity, Starboard Value continues to own 8.7% of Algonquin Power's outstanding stock. Algonquin shares have gained roughly 13.4% since the beginning of 2025.

Increases in Holdings

Victoria's Secret $(VSCO)$ BBRC International raised its stake in the women's lounge- and sleepwear maker to 9,175,019 shares. BBRC did so through the purchase of 1,572,000 Victoria's Secret shares from March 6 through March 11, 2025, at per share prices ranging from $16.18 to $20.

Following the latest purchases, BBRC owns 11.7% of Victoria's Secret's outstanding stock. Shares of Victoria's Secret have lost nearly half of their value since the beginning of 2025.

Bitdeer Technologies Group (BTDR) Tether Holdings raised its stake in the blockchain specialist to 31,891,689 shares. The cryptocurrency company bought 1,825,000 Bitdeer Technologies shares from Feb. 26 through March 13, 2025, at per share prices ranging from $9.89 to $10.

Following the latest purchases, Tether Holdings owns 21.4% of Bitdeer Technologies' outstanding stock. Shares of Bitdeer have lost about 53.8% of their value since the beginning of this year.

Decreases in Holdings

Disc Medicine (IRON) OrbiMed Advisors lowered its stake in the clinical-stage biopharmaceutical company to 1,556,369 shares. OrbiMed did so through the sale of 229,202 Disc Medicine shares from March 10 through March 11, 2025, at per share prices ranging from $54.01 to $55.01.

Following the latest sales, OrbiMed Advisors continues to own 4.5% of Disc Medicine's outstanding stock, placing it below the 5% threshold that would require OrbiMed to report further Disc Medicine purchases or sales. Shares of Disc Medicine have lost roughly 14% of their value since the start of 2025.

Innoviva $(INVA)$ Sarissa Capital Management lowered its stake in the biotechnology company to 2,966,022 shares. Sarissa Capital Management did so through the sale of 2,271,139 Innoviva shares from March 10 through March 13, 2025, at per share prices ranging from $17 to $17.76.

Following the latest sales, Sarissa Capital Management continues to own 4.7% of Innoviva's outstanding stock. Shares of Innoviva have remained mostly flat since the start of 2025.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 21, 2025 18:35 ET (22:35 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.